ShaliniShenoyMDProfessor of Pediatrics

Pediatric Hematologic Oncology

Medical Director, Pediatric Stem Cell Transplant Program

Dr. Shenoy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1 Childrens Pl
# Div
Saint Louis, MO 63110
Phone+1 314-454-6018

Fax+1 844-621-4392

Washington University/B-JH/SLCH ConsortiumFellowship, Pediatric Hematology/Oncology, 1992 - 1995
Louisiana State University School of MedicineResidency, Pediatrics, 1989 - 1991
Kasturba Medical College ManipalClass of 1985, MBBS, MD

Abatacept as GVHD Prophylaxis Phase 2 Start of enrollment: 2013 Feb 01
Active, not recruiting
Phase 2

PubMed

Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD.
Lev Gorfinkel, Sharmila Raghunandan, Benjamin Watkins, Kyle Hebert, Donna S Neuberg
Bone Marrow Transplantation. 2024-05-01
1 citations
Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial.
Mary Eapen, Jianqun Kou, Martin Andreansky, Monica Bhatia, Joel Brochstein
American Journal of Hematology. 2024-04-01
2 citations
Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.
Ashley V Geerlinks, Brooks Scull, Christa Krupski, Ryan Fleischmann, Michael A Pulsipher
Blood Advances. 2023-07-25

Abstracts/Posters

Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Pa...
Shalini Shenoy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)
Shalini Shenoy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the...
Shalini Shenoy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018